Potent inhibition of yeast-expressed CYP2D6 by dihydroquinidine, quinidine, and its metabolites.

No abstract is available for this paper.

• Publication year

  1995

• Venue

  Biochemical Pharmacology

• Publication date

  1995-09-07

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/0006-2952(95)00207-GPMID 7575645
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Isolation, characterisation and synthesis of a new quinidine metabolite

  2010cited by this paper
• Berichten

  2005cited by this paper
• Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians.

  1994cited by this paper
• Metabolic polymorphisms.

  1993cited by this paper
• Interaction of the enantiomers of fluoxetine and norfluoxetine with human liver cytochromes P450.

  1993cited by this paper
• The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes.

  1992cited by this paper
• Catalytic activities of human debrisoquine 4-hydroxylase cytochrome P450 (CYP2D6) expressed in yeast.

  1992cited by this paper
• Inhibition of debrisoquin clearance in perfused rat livers and inhibition of dextromethorphan metabolism in human liver microsomes by 4-hydroxydebrisoquin or other metabolites of debrisoquin.

  1992cited by this paper
• The expression of human cytochrome P450IA1 in the yeast Saccharomyces cerevisiae.

  1991cited by this paper
• Comparative effects of the diastereoisomers, quinine and quinidine in producing phenocopy debrisoquine poor metabolisers (PMs) in healthy volunteers.

  1991cited by this paper
• Fluoxetine and norfluoxetine are potent inhibitors of P450IID6--the source of the sparteine/debrisoquine oxidation polymorphism.

  1991cited by this paper
• Expression of human liver cytochrome P450 IIIA4 in yeast. A functional model for the hepatic enzyme.

  1990cited by this paper
• The genetic polymorphism of debrisoquine/sparteine metabolism--clinical aspects.

  1990cited by this paper
• Synthesis of 10,11-dihydroxydihydroquinidine N-oxide, a new metabolite of quinidine. Preparation and 1H-nmr spectroscopy of the metabolites of quinine and quinidine and conformational analysis via 2D COSY nmr spectroscopy.

  1990cited by this paper
• Catalytic activities of human liver cytochrome P-450 IIIA4 expressed in Saccharomyces cerevisiae.

  1990cited by this paper
• Dextromethorphan O‐demethylation in liver microsomes as a prototype reaction to monitor cytochrome P‐450 db1 activity

  1989cited by this paper
• Effect of quinidine on the dextromethorphan O-demethylase activity of microsomal fractions from human liver.

  1989cited by this paper
• Plasma concentrations of quinidine, its major metabolites, and dihydroquinidine in patients with torsades de pointes

  1988cited by this paper
• In vitro evidence against the oxidation of quinidine by the sparteine/debrisoquine monooxygenase of human liver.

  1988cited by this paper
• High-performance liquid chromatographic assays for bufuralol 1'-hydroxylase, debrisoquine 4-hydroxylase, and dextromethorphan O-demethylase in microsomes and purified cytochrome P-450 isozymes of human liver.

  1987cited by this paper
• Quinidine and the identification of drugs whose elimination is impaired in subjects classified as poor metabolizers of debrisoquine.

  1986cited by this paper
• Oxidation of quinidine by human liver cytochrome P-450.

  1986cited by this paper
• Competitive inhibition of sparteine oxidation in human liver by beta-adrenoceptor antagonists and other cardiovascular drugs.

  1984cited by this paper
• A simplified high-pressure liquid chromatography method for determining lipophilicity for structure-activity relationships.

  1983cited by this paper

• Elucidation of the compatibility mechanism of Yuanhuzhitong prescription in view of CYP-mediated herbal inter-component interactions.

  2025cites this paper
• Physiologically Based Pharmacokinetic Modeling of Quinidine to Establish a CYP3A4, P-gp and CYP2D6 Drug-Drug-Gene Interaction Network.

  2023cites this paper
• In vitro inhibitory effects of glucosamine, chondroitin and diacerein on human hepatic CYP2D6

  2021cites this paper
• AVP-786 as a promising treatment option for Alzheimer’s Disease including agitation

  2021influential citation
• In vitro inhibitory effects of glucosamine, chondroitin and diacerein on human hepatic CYP2D6

  2021cites this paper
• Physiologically Based Pharmacokinetic Modeling to Assess the Impact of CYP2D6‐Mediated Drug‐Drug Interactions on Tramadol and O‐Desmethyltramadol Exposures via Allosteric and Competitive Inhibition

  2021cites this paper
• Identifying cytochrome P450s involved in oxidative metabolism of synthetic cannabinoid N‐(adamantan‐1‐yl)‐1‐(5‐fluoropentyl)‐1H‐indole‐3‐carboxamide (STS‐135)

  2020cites this paper
• Accurate Estimation of In Vivo Inhibition Constants of Inhibitors and Fraction Metabolized of Substrates with Physiologically Based Pharmacokinetic Drug–Drug Interaction Models Incorporating Parent Drugs and Metabolites of Substrates with Cluster Newton Method

  2018cites this paper
• Prediction of drug‐drug interactions using physiologically‐based pharmacokinetic models of CYP450 modulators included in Simcyp software

  2018cites this paper
• Sodium tanshinone IIA sulfonate and its interactions with human CYP450s

  2016cites this paper
• Guanfu Base A, an Antiarrhythmic Alkaloid of Aconitum coreanum, Is a CYP2D6 Inhibitor of Human, Monkey, and Dog Isoforms

  2015cites this paper
• Guanfu base A, an antiarrhythmic alkaloid of Aconitum coreanum is a CYP2D6 inhibitor of human, monkey, and dog isoforms

  2015cites this paper
• Guanfu base A, an antiarrhythmic alkaloid of Aconitum coreanum is a CYP2D6 inhibitor of human, monkey, and dog isoforms

  2015cites this paper
• SYSTEM-DEPENDENT METABOLISM OF DRUGS BY CYTOCHROME P450: THE MECHANISTIC BASIS FOR WHY HUMAN LIVER MICROSOMES ARE SUPERIOR TO HUMAN HEPATOCYTES AT METABOLIZING MIDAZOLAM BUT INFERIOR AT METABOLIZING DESLORATADINE

  2015cites this paper
• Searching the Cytochrome P450 Enzymes for the Metabolism of Meranzin Hydrate: A Prospective Antidepressant Originating from Chaihu-Shugan-San

  2014cites this paper
• Investigating the chemical space and metabolic bioactivation of natural products and cross-reactivity of chemical inhibitors in CYP450 phenotyping

  2014cites this paper
• Prediction of pharmacokinetic behaviour by combining in vivo and in vitro data in physiologically based pharmacokinetic (PBPK) model: Parameter estimation and sensitivity analysis

  2012cites this paper
• Spectral accuracy of a new hybrid quadrupole time-of-flight mass spectrometer: application to ranking small molecule elemental compositions.

  2012cites this paper
• Are Circulating Metabolites Important in Drug–Drug Interactions?: Quantitative Analysis of Risk Prediction and Inhibitory Potency

  2011cites this paper
• Chemical inhibitors of cytochrome P450 isoforms in human liver microsomes: a re-evaluation of P450 isoform selectivity

  2011cites this paper
• New insights into the structural characteristics and functional relevance of the human cytochrome P450 2D6 enzyme

  2009influential citation
• Medicinal chemistry strategies to reduce CYP2D6 inhibitory activity of lead candidates.

  2009cites this paper
• Scaling of in Vitro Membrane Permeability to Predict P-glycoprotein-Mediated Drug Absorption in Vivo

  2008cites this paper
• Inactivation of CYP2D6 by methylenedioxymethamphetamine in different recombinant expression systems.

  2007cites this paper
• [The influence of clomipramine on CYP2D6 activity].

  2007cites this paper
• Evaluation of 227 Drugs for In Vitro Inhibition of Cytochrome P450 2B6

  2006cites this paper
• The impact of experimental design on assessing mechanism-based inactivation of CYP2D6 by MDMA (Ecstasy)

  2006cites this paper
• A novel incubation direct injection LC/MS/MS technique for in vitro drug metabolism screening studies involving the CYP 2D6 and the CYP 3A4 isozymes.

  2005cites this paper
• Examination of 209 Drugs for Inhibition of Cytochrome P450 2C8

  2005cites this paper
• Metabolism of antiarrhythmics.

  2004cites this paper
• Determination of the human cytochrome P450s involved in the metabolism of 2n -propylquinoline

  2003influential citation
• Inhibition of cytochrome P450 2D6: structure-activity studies using a series of quinidine and quinine analogues.

  2003cites this paper
• Comparative molecular field analysis and QSAR on substrates binding to cytochrome p450 2D6.

  2003cites this paper
• Classic histamine H1 receptor antagonists: a critical review of their metabolic and pharmacokinetic fate from a bird's eye view.

  2003cites this paper
• Physiologically based modelling of inhibition of metabolism and assessment of the relative potency of drug and metabolite: dextromethorphan vs. dextrorphan using quinidine inhibition.

  2003cites this paper
• Summary of information on human CYP enzymes: human P450 metabolism data

  2002cites this paper
• Expression, Purification, Biochemical Characterization, and Comparative Function of Human Cytochrome P450 2D6.1, 2D6.2, 2D6.10, and 2D6.17 Allelic Isoforms

  2002influential citation
• Comparative contribution to dextromethorphan metabolism by cytochrome P450 isoforms in vitro: can dextromethorphan be used as a dual probe for both CTP2D6 and CYP3A activities?

  2001influential citation
• Pharmacokinetic Interactions of Antimalarial Agents

  2001cites this paper
• Differential inhibition of human CYP1A1 and CYP1A2 by quinidine and quinine

  2001cites this paper
• A method for the simultaneous evaluation of the activities of seven major human drug-metabolizing cytochrome P450s using an in vitro cocktail of probe substrates and fast gradient liquid chromatography tandem mass spectrometry.

  2001cites this paper
• Pharmacokinetics of selective serotonin reuptake inhibitors.

  2000cites this paper
• Identification of the cytochrome P450 enzymes involved in the metabolism of cisapride: in vitro studies of potential co‐medication interactions

  2000influential citation
• The role of CYP2C19 in the metabolism of (+/-) bufuralol, the prototypic substrate of CYP2D6.

  1999cites this paper
• Applications of Heterologous Expressed and Purified Human Drug-Metabolizing Enzymes: An Industrial Perspective

  1999cites this paper
• Molecular cloning, expression, and characterization of CYP2D17 from cynomolgus monkey liver.

  1999cites this paper
• Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes

  1999cites this paper
• Enzymes in addition to CYP3A4 and 3A5 mediate N‐demethylation of dextromethorphan in human liver microsomes

  1999cites this paper
• Polymorphic Cytochromes P450 and Drugs Used in Psychiatry

  1999cites this paper
• Rapid characterization of the major drug-metabolizing human hepatic cytochrome P-450 enzymes expressed in Escherichia coli.

  1999influential citation
• Fully automated analysis of activities catalysed by the major human liver cytochrome P450 (CYP) enzymes: assessment of human CYP inhibition potential.

  1999cites this paper
• In Vivo and In Vitro Recombinant DNA Technology as a Powerful Tool in Drug Development

  1999cites this paper
• Inhibition and induction of human cytochrome P450 (CYP) enzymes.

  1998cites this paper
• Identification and Characterization of Human Cytochrome P 450 Isoforms Interacting with Pimozide 1

  1998cites this paper
• Expression and characterization of dog CYP2D15 using baculovirus expression system.

  1998cites this paper
• Metabolism of dexfenfluramine in human liver microsomes and by recombinant enzymes: role of CYP2D6 and 1A2.

  1998cites this paper
• Identification and characterization of human cytochrome P450 isoforms interacting with pimozide.

  1998cites this paper
• A major role for CYP2A6 in nicotine C-oxidation by human liver microsomes.

  1997cites this paper
• Pharmacokinetics and Pharmacodynamics of Intravenous Agents for Ventricular Arrhythmias

  1997cites this paper
• The in vitro interaction of dexmedetomidine with human liver microsomal cytochrome P4502D6 (CYP2D6).

  1997cites this paper
• Role of CYP2D6 in the N-hydroxylation of procainamide.

  1997cites this paper
• Use of In Vitro and In Vivo Data to Estimate the Likelihood of Metabolic Pharmacokinetic Interactions

  1997cites this paper
• The in vitro interaction of dexmedetomidine with human liver microsomal cytochrome P4502D6 (CYP2D6).

  1997cites this paper
• Inhibition of coumarin 7-hydroxylase activity in human liver microsomes.

  1997cites this paper
• Propranolol hydroxylation and N-desisopropylation by cytochrome P4502D6: studies using the yeast-expressed enzyme and NADPH/O2 and cumene hydroperoxide-supported reactions.

  1996cites this paper